Form 10-Q REGENERON PHARMACEUTICAL For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Leerink: 'We continue to recommend REGN shares'
August 4, 2025 10:20 AM EDTLeerink Partners analyst Andrew Berens reiterated an Outperform rating and $645.00 price target on Regeneron Pharma (NASDAQ: REGN).
The analyst comments "Bottom Line: We continue to recommend REGN shares based upon improving growth prospects and attractive valuation. We project 5-yr (2025-2030) CAGR rev +7% and EPS +10%. Mgmt emphasized Lynozyfics... More
